Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.6044 USD -2.62% Intraday chart for Traws Pharma, Inc. -7.44% -18.94%
May. 07 Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy CI
Apr. 04 North American Morning Briefing : Focus Turns to -2- DJ

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Travatrelvir, an Inhibitor of SARS CoV 2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir
PU
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
GL
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Traws Pharma : Targeting the RAS/RAF/PI3K pathway for CD40 induction in melanoma cells to overcome resistance to anti-PD1 immunotherapies
PU
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
GL
Traws Pharma Announces New Employee Inducement Grants
AQ
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
AQ
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
AQ
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
AQ
Onconova Therapeutics Preclinical Narazaciclib Data At SABCS Highlights Differentiated Anti-Tumor Activity V. Other CDK4/6i's
AQ
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
AQ
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets Nineteenth Annual Emerging Growth Equity Conference
AQ
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
AQ
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
AQ
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
AQ
Poster Presentation Monday, Dec. 11th 6:00-8:00p PT
PU
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
AQ
Onconova Expands Leadership Team with Two Key Appointments
AQ
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
AQ
Encouraging Rigosertib Data Presented at EADV as Late Breaker
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. News Traws Pharma, Inc.
  5. Press Releases